A computable biomedical knowledge object for calculating in-hospital mortality for patients admitted with acute myocardial infarction.

Quality indicators play an essential role in a learning health system. They help healthcare providers to monitor the quality and safety of care delivered and to identify areas for improvement. Clinical quality indicators, therefore, need to be based on real world data. Generating reliable and actionable data routinely is challenging. Healthcare data are often stored in different formats and use different terminologies and coding systems, making it difficult to generate and compare indicator reports from different sources. The Observational Health Sciences and Informatics community maintains the Observational Medical Outcomes Partnership Common Data Model (OMOP). This is an open data standard providing a computable and interoperable format for real world data. We implemented a Computable Biomedical Knowledge Object (CBK) in the Piano Platform based on OMOP. The CBK calculates an inpatient quality indicator and was illustrated using synthetic electronic health record (EHR) data in the open OMOP standard. The CBK reported the in-hospital mortality of patients admitted for acute myocardial infarction (AMI) for the synthetic EHR dataset and includes interactive visualizations and the results of calculations. Value sets composed of OMOP concept codes for AMI and comorbidities used in the indicator calculation were also created. Computable biomedical knowledge (CBK) objects that operate on OMOP data can be reused across datasets that conform to OMOP. With OMOP being a widely used interoperability standard, quality indicators embedded in CBKs can accelerate the generation of evidence for targeted quality and safety management, improving care to benefit larger populations.

Informations de copyright

© 2023 Evidentli Pty Ltd. Learning Health Systems published by Wiley Periodicals LLC on behalf of University of Michigan.

Déclaration de conflit d'intérêts

Rosemarie Sadsad, Gema Ruber, Steven Nicklin, and Guy Tsafnat are employed by Evidentli Pty Ltd and as such hold securities tied to the success of the company. Guy Tsafnat is also a director and major shareholder. None of the authors are associated with the ACSQHC, nor with any company or product related to myocardial disease.